NCT02589756

Brief Summary

Obesity represents one of the most important public health challenges for the societies. Although excess energy intake and physical inactivity are major causes of obesity and cardiometabolic disorders, emerging evidence has linked persistent organic pollutants (POPs) with the global epidemic of type 2 diabetes. However, the potential impacts of POPs on obesity and cardiometabolic risk in humans remain poorly known. On the other side systematic reviews and meta-analyses conducted in recent years strongly support a protective association between eating nuts and CVD. The investigators will conduct a randomized controlled clinical trial in adults. The main research questions are: a. Does consumption of fatty fish increase levels of POPs in overweight and obese adult norwegian men and women compared to a control group not consuming fatty fish? b. Does consumption of fatty fish affect markers of cardiometabolic risks (blood pressure, lipids, glucose and CRP) in overweight and obese adult norwegian men and women compared to a control group not consuming fatty fish? c. Does consumption of nuts improve markers of cardiometabolic risks in overweight and obese adult Norwegian men and women compared:1. to a control group not consuming nuts or fatty fish and 2. to a group consuming fatty fish. Clinical significance of study: If an increase in POP levels is seen, and correlates with cardiometabolic risks, this may indicate the need to look further at a causal relation between POPs and cardiometabolic disease and risk factors particularly type 2 diabetes. If eating nuts improves CVD risk factors compared to not eating nuts, or to eating fatty fish, this could be important dietary information for populations at high risk of CVD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable obesity

Timeline
Completed

Started Sep 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2015

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

September 14, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 28, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 11, 2017

Completed
Last Updated

May 11, 2020

Status Verified

May 1, 2020

Enrollment Period

2 years

First QC Date

September 14, 2015

Last Update Submit

May 8, 2020

Conditions

Keywords

obesitypersistent organic pollutantsmetabolic syndrome

Outcome Measures

Primary Outcomes (1)

  • persistent organic pollutants

    Measuring of persistent organic pollutants' levels before and after intervention. Blood tests will be obtained at randomization, and six months of follow-up for analysis analysis of environmental pollutants including 21 POPs in g/mol .Six-month follow-up samples will be stored for future analyses.

    6 months

Secondary Outcomes (10)

  • waist circumference

    6 months

  • Parameter of inflammation CRP (C-reactive protein)

    6 months

  • Parameter of insulin resistance HOMA index

    6 months

  • C-peptide

    6 months

  • Insulin

    6 months

  • +5 more secondary outcomes

Study Arms (3)

The fatty fish group

EXPERIMENTAL

Participants will eat fatty fish and avoiding nuts)

Other: The nut groupOther: The control group

The nut group

EXPERIMENTAL

Participants who will avoid fatty fish

Other: The fatty fish groupOther: The control group

The control group

PLACEBO COMPARATOR

Participants who will avoid both fatty fish and nuts

Other: The fatty fish groupOther: The nut group

Interventions

At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.

The control groupThe nut group

At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.

The control groupThe fatty fish group

After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.

The fatty fish groupThe nut group

Eligibility Criteria

Age40 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women aged 40 to 65 years
  • BMI in the overweight (25-29.9) or obese (30-34.9)
  • Range and components of metabolic syndrome (waist circumference \>102 cm for men or \>94 cm for women; fasting glucose \>5.6 mmol/l, HDL cholesterol \<1.3 for women or \<1.0 for men, and triglycerides \>1.7 mmol/l)
  • Fertile women are required to use reliable contraception

You may not qualify if:

  • Cigarette smoking
  • Diabetes mellitus
  • Allergy or dislike of fish
  • allergy or dislike of nuts
  • chronic disease
  • morbid obesity due to ethical reasons and weight fluctuations
  • eating disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oslo University Hospital, UllevÄl

Oslo, Norway

Location

Related Publications (5)

  • Ngwa EN, Kengne AP, Tiedeu-Atogho B, Mofo-Mato EP, Sobngwi E. Persistent organic pollutants as risk factors for type 2 diabetes. Diabetol Metab Syndr. 2015 Apr 30;7:41. doi: 10.1186/s13098-015-0031-6. eCollection 2015.

    PMID: 25987904BACKGROUND
  • Schecter A, Colacino J, Haffner D, Patel K, Opel M, Papke O, Birnbaum L. Perfluorinated compounds, polychlorinated biphenyls, and organochlorine pesticide contamination in composite food samples from Dallas, Texas, USA. Environ Health Perspect. 2010 Jun;118(6):796-802. doi: 10.1289/ehp.0901347. Epub 2010 Feb 10.

    PMID: 20146964BACKGROUND
  • Tan SY, Dhillon J, Mattes RD. A review of the effects of nuts on appetite, food intake, metabolism, and body weight. Am J Clin Nutr. 2014 Jul;100 Suppl 1:412S-22S. doi: 10.3945/ajcn.113.071456. Epub 2014 Jun 11.

    PMID: 24920033BACKGROUND
  • Orem A, Yucesan FB, Orem C, Akcan B, Kural BV, Alasalvar C, Shahidi F. Hazelnut-enriched diet improves cardiovascular risk biomarkers beyond a lipid-lowering effect in hypercholesterolemic subjects. J Clin Lipidol. 2013 Mar-Apr;7(2):123-31. doi: 10.1016/j.jacl.2012.10.005. Epub 2012 Oct 26.

    PMID: 23415431BACKGROUND
  • Dusanov S, Svendsen M, Ruzzin J, Kiviranta H, Gulseth HL, Klemsdal TO, Tonstad S. Effect of fatty fish or nut consumption on concentrations of persistent organic pollutants in overweight or obese men and women: A randomized controlled clinical trial. Nutr Metab Cardiovasc Dis. 2020 Mar 9;30(3):448-458. doi: 10.1016/j.numecd.2019.11.006. Epub 2019 Nov 21.

MeSH Terms

Conditions

ObesityMetabolic SyndromeDiabetes Mellitus

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsInsulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Study Officials

  • Kare I Birkeland, MD, Ph.D

    Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Norway

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD candidate

Study Record Dates

First Submitted

September 14, 2015

First Posted

October 28, 2015

Study Start

September 1, 2015

Primary Completion

September 1, 2017

Study Completion

September 11, 2017

Last Updated

May 11, 2020

Record last verified: 2020-05

Locations